April 15, 2011 08:59 ET

Equity Research on Teva Pharmaceutical Industries Limited and Forest Laboratories Inc. -- Drug Manufacturers Taking Different Approaches

NEW YORK, NY--(Marketwire - Apr 15, 2011) - has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Drug Manufacturers - Other industry and are offering free analytical research on Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) and Forest Laboratories Inc. (NYSE: FRX). Register with us today at to have free access to this research or speak to one of our pros at

Expiring exclusivity rights are the biggest concern to drug manufacturers at the moment. To offset the earnings losses that come with generic drug production, companies within the drug manufacturing industry are taking different approaches. Ultimately though, the goal of these approaches is to maintain a steady pipeline of drugs to market. Get instant analyses of Teva Pharmaceutical Industries Limited and Forest Laboratories Inc. from live, real-time experts standing by at There is no commitment to join. is the Ultimate Trading Environment for investors. If you are considering owning Teva Pharmaceutical Industries Limited and Forest Laboratories Inc. then you should sign up for a free membership and our complimentary reports today at Over the last 5 years our returns outpaced any of the major indexes. Sign up today to find out what you are missing.

Forest Pharmaceuticals Inc. which faces expiring exclusivity on some of its Alzheimer treatments, recently acquired Clinical Data. Clinical Data produces a variety of drugs and has a strong track record of Food and Drug Administration approval. Forest Laboratories Inc. report is accessible for free by registering today at

Some companies are taking a more traditional approach and are successfully getting drugs through FDA approval processes and clinical trials. Teva Pharmaceutical Industries Ltd. recently reported successful phase III results of a two year Multiple Sclerosis drug trial. The FDA is currently reviewing a testosterone gel licensed to Teva as well. Teva Pharmaceutical Industries Limited report is accessible for free by registering today at
Moving forward, drug manufacturers are taking different approaches to expiring patents and maintaining a consistent pipeline of drugs to market. The industry as a whole has been strong lately and companies within the industry which are getting more drugs on the market via acquisitions or FDA approval seem well positioned for growth in 2011.

The two Drug Manufacturers - Other stocks research reports are available for free by signing up now on


Shine's Room Online is the brain child of David Shine, a 15 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link

Contact Information